The US Food and Drug Administration (FDA) has sent Merck & Co a
warning letter saying it has failed to correct a number of
manufacturing deficiencies at its main vaccine manufacturing plant
in West Point, Pennsylvania.
Merck Serono intends to forge ahead with severing its investment in
diabetes and either sell or partner out its existing research and
development (R&D) activities in this field, which it no longer
feels able to compete in effectively.
For the first time Merck has opened the doors of its
under-construction manufacturing plant in North Carolina to public
officials, boasting it will eventually contribute about two-thirds
of its annual live-virus vaccine production.